ProQR Therapeutics N.V. announced the closing of its previously announced underwritten public offering of 18,000,000 ordinary shares. The shares were sold at a public offering price of $3.50 per share, resulting in total gross proceeds of $63.0 million.
Additionally, the company confirmed the closing of its concurrent private placement of 3,523,538 ordinary shares to Eli Lilly and Company. This private placement generated approximately $12.3 million in gross proceeds, with shares also priced at $3.50 each.
The successful closing of these financing activities provides ProQR with a combined gross capital infusion of $75.3 million. These funds are designated to support the company's ongoing research and development efforts, clinical programs, and general corporate needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.